PROFIT & LOSS FORECAST £
2020/21
2021/22
2022/23
2023/24
2024/25
5,934,683
28,650,318
69,051,703
130,102,988
205,628,460
455%
383%
141%
88%
58%
Direct Costs
4,221,161
16,779,406
37,002,075
66,609,747
99,037,552
Gross Profit
1,713,522
11,870,912
32,049,627
63,493,240
106,590,908
GP%
28.9%
41.4%
46.4%
48.8%
51.8%
Salaries & Wages
648,360
1,216,720
2,188,680
2,906,640
3,571,200
Overheads
660,200
1,643,400
3,075,780
4,974,600
8,342,640
EBITDA
404,962
9,010,792
26,785,167
55,612,000
94,677,068
Sales
Operating Expenses
EBITDA %
6.8%
31.5%
38.8%
42.7%
46.0%
Depreciation & Amortisation
100,000
150,000
200,000
250,000
300,000
EBIT
304,962
8,860,792
26,585,167
55,362,000
94,377,068 45.9%
EBIT %
5.1%
30.9%
38.5%
42.6%
Interest
0
0
0
0
0
Taxation
93,798
1,683,550
5,051,182
10,518,780
17,931,643
Retained Profit
211,164
7,177,241
21,533,985
44,843,220
76,445,424
3.6%
25.1%
31.2%
34.5%
37.2%
511,164
7,777,241
22,433,985
46,343,220
78,545,424
5.2%
44.3%
56.1%
53.7%
47.6%
Total Shareholder Funds
9,786,580
17,563,821
39,997,807
86,341,027
164,886,452
Cash at End of Period
4,255,510
6,647,625
24,954,802
61,948,465
133,256,963
Comprehensive Income
CONFIDENTIAL - DO NOT DISSEMINATE. This business plan contains confidential, trade-secret information and is shared only with the understanding that you will not share its contents or ideas with third parties without the express written consent of the plan author.
20 Medicaleaf
